Sanofi (SNY)

39.15
0.44 1.11
NYSE : Health Technology
Prev Close 39.59
Open 39.05
Day Low/High 38.97 / 39.28
52 Wk Low/High 37.43 / 50.65
Volume 2.55M
Avg Volume 1.50M
Exchange NYSE
Shares Outstanding 2.58B
Market Cap 99.65B
EPS 1.70
P/E Ratio 21.47
Div & Yield 1.20 (3.21%)
5 Things You Must Know Before the Market Opens Wednesday

5 Things You Must Know Before the Market Opens Wednesday

U.S. stock futures are mixed ahead of a decision on interest rates and fresh economic forecasts from the Fed; tech giants meet with Donald Trump; IBM's Rometty promises jobs.

Actelion Shares Plunge After J&J Drops Potential $27 Billion Takeover

Actelion Shares Plunge After J&J Drops Potential $27 Billion Takeover

Actelion confirms the end of talks with J&J over a $27 billion takeover, and market focus shifts to France's Sanofi.

European Stocks Fall as Investors Take Cautious Stance Ahead of Fed Meeting

European Stocks Fall as Investors Take Cautious Stance Ahead of Fed Meeting

European stocks are set to open lower Wednesday ahead of the Fed's final policy meeting of 2016.

5 Things You Must Know Before the Market Opens Tuesday

5 Things You Must Know Before the Market Opens Tuesday

U.S. stock futures trade flat following another record close for the Dow; Amazon reportedly envisions opening 2,000 brick-and-mortar grocery stores; Apple Watch sales set a record, Apple CEO says.

European Stocks Slip Lower, Italy Gains in Mixed Start to Trading

European Stocks Slip Lower, Italy Gains in Mixed Start to Trading

European markets are set for a positive open Tuesday after Asia traders booked their best single-day gains in two weeks.

Actelion Surges on Report of Sanofi Challenge to J&J Takeover Bid

Actelion Surges on Report of Sanofi Challenge to J&J Takeover Bid

Actelion shares are on the rise again on reports of a potential counter-bid from France's Sanofi.

Sanofi Genzyme Announces Start Of Phase III Study Of Isatuximab For Relapsed And Refractory Multiple Myeloma

Sanofi Genzyme Announces Start Of Phase III Study Of Isatuximab For Relapsed And Refractory Multiple Myeloma

Sanofi Genzyme, the specialty care global business unit of Sanofi, today announced the initiation of the ICARIA-MM Phase III trial of isatuximab, an investigational anti-CD38 monoclonal antibody being studied for the...

Actelion Shares Fall Sharply on Report It Is Resisting $17 Billion J&J Takeover

Actelion Shares Fall Sharply on Report It Is Resisting $17 Billion J&J Takeover

Actelion shares traded sharply lower Tuesday following reports it's looking at strategies that would keep it independent from a $17 billion approach from Johnson & Johnson.

Amicus Tumbles on Lengthy Delay to U.S. Fabry Drug FDA Filing Plan

Amicus Tumbles on Lengthy Delay to U.S. Fabry Drug FDA Filing Plan

The U.S. Food and Drug Administration turned down Amicus' request to seek accelerated approval for Galafold based on an existing kidney biomarker data.

Dow, Lifted by Financials, Finishes at Record High; Nasdaq Slips

Dow, Lifted by Financials, Finishes at Record High; Nasdaq Slips

Wall Street runs at two speeds as a rally in financials sent the Dow Jones Industrial Average to close at records, while a selloff in tech sank the Nasdaq.

Dow Hits New Records, Nasdaq Falls as Tech Stocks Decline

Dow Hits New Records, Nasdaq Falls as Tech Stocks Decline

Wall Street remains divided on Thursday as investors try to gauge the types of policies president-elect Donald Trump could enact.

MannKind Is Still Too Heavy to Avoid the Afrezza Crash Landing

MannKind Is Still Too Heavy to Avoid the Afrezza Crash Landing

MannKind bulls -- the rainbow-hued unicorns of the investment world -- believe the company's marketing efforts will succeed. They're wrong.

Here's Which Pharma Giants Might Want to Buy Pfizer's Consumer Health Unit

Here's Which Pharma Giants Might Want to Buy Pfizer's Consumer Health Unit

A sale or spinoff of this business will likely get the attention of competitors that want to increase their over-the-counter product units.

S&P 500, Nasdaq Turn Red in Erratic Post-Election Trading

S&P 500, Nasdaq Turn Red in Erratic Post-Election Trading

Wall Street runs at two speeds on Thursday with the Dow Jones Industrial Average setting a record high and the S&P 500 and Nasdaq slipping.

Stock Futures Rise as Wall Street Rally Continues After Trump's Win

Stock Futures Rise as Wall Street Rally Continues After Trump's Win

Stock futures move higher on Thursday with the Dow Jones Industrial Average set to open at a high.

Donald Trump Election Victory Boosts Some Stocks and Sectors

Donald Trump Election Victory Boosts Some Stocks and Sectors

As we all know, the stock market and the economy abhor uncertainty.

The Likely Market Impact of President Trump

As we all know, the stock market and the economy abhor uncertainty.

The Likely Market Impact of President Trump

As we all know, the stock market and the economy abhor uncertainty.

5 Things You Must Know Before the Market Opens Wednesday

5 Things You Must Know Before the Market Opens Wednesday

Stock futures are tumbling Wednesday but are well off their lows as Republican Donald Trump is elected the next president of the United States in a surprising victory.

European Drug Companies Get an Injection From Trump Victory

European Drug Companies Get an Injection From Trump Victory

The threat of a government clampdown on drug prices is off the table with Clinton's defeat, while wider support for defensive stocks helped push pharmaceuticals higher.

Gilead Sciences' Next Challenge to Incyte's Myelofibrosis Drug Dominance

Gilead Sciences' Next Challenge to Incyte's Myelofibrosis Drug Dominance

Gilead Sciences is nearing the completion of two phase III studies of the Jak inhibitor momelotinib in myelofibrosis, a disease affecting bone marrow.

Alexion Soars, Then Falls Amid Takeover Rumors

Alexion Soars, Then Falls Amid Takeover Rumors

The biotech company cancelled its conference appearance and took its time filing its Form 10-Q with the Securities and Exchange Commission.

Sanofi Genzyme Begins Pivotal Phase 3 Trial Of NeoGAA Investigational Second-Generation Therapy For Pompe Disease

Sanofi Genzyme Begins Pivotal Phase 3 Trial Of NeoGAA Investigational Second-Generation Therapy For Pompe Disease

Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today that the first patient has been enrolled and received an infusion in a pivotal Phase 3 clinical trial named COMET for the...

The Internet of Things Is Transforming Healthcare, but There's One Huge Risk

The Internet of Things Is Transforming Healthcare, but There's One Huge Risk

Tech giants, Big Pharma and insurers are all angling to profit from the $3 trillion-plus U.S. healthcare market.

Closing Bell: Regeneron Slides on FDA Ruling; FBI Reopens Clinton Case

Closing Bell: Regeneron Slides on FDA Ruling; FBI Reopens Clinton Case

It was a volatile end to the week after federal investigators reopened a case into Hillary Clinton's email server.

European Stocks Mixed on Divergence in Economic Data, Mixed Earnings

European Stocks Mixed on Divergence in Economic Data, Mixed Earnings

Economic data in France disappoints; Germany and U.K. beat expectations.

Buy Drug Maker Sanofi After It Surpassed Third-Quarter Estimates

Buy Drug Maker Sanofi After It Surpassed Third-Quarter Estimates

The pharmaceutical company reported better-than-expected results on Friday morning. Grab its ADRs now.

European Stocks Slip After French GDP Miss; Novo Nordisk Plunges on U.S. Woes

European Stocks Slip After French GDP Miss; Novo Nordisk Plunges on U.S. Woes

Pharma group Sanofi rises on improved guidance and RBS gains after a third-quarter profit beat.

What to Look for When Sanofi (SNY) Reports Q3 Results

What to Look for When Sanofi (SNY) Reports Q3 Results

Analysts are expecting to see a year-over-year decline in earnings and revenue when Sanofi (SNY) posts 2016 third-quarter results before Friday's market open.

Novo Nordisk Takes Axe to Workforce as Growth Falters

Novo Nordisk Takes Axe to Workforce as Growth Falters

The Danish pharmaceuticals maker is facing tighter margins and tougher competition in the U.S.

TheStreet Quant Rating: C+ (Hold)